Zenosense, Inc. Extends License to Include Cancer Applications
08 Mai 2014 - 2:30PM
Marketwired
Zenosense, Inc. Extends License to Include Cancer Applications
VALENCIA, SPAIN--(Marketwired - May 8, 2014) - Zenosense, Inc.
(OTCQB: ZENO) (the "Company"), a healthcare technology company
focused on developing and marketing a device for use in hospitals
and other healthcare settings to detect the Methicillin-resistant
Staphylococcus aureus (MRSA) "Super-Bug," is pleased to announce
that the Company has extended its agreement with the Sgenia Group
("Sgenia") to include cancer sensory devices.
Under the terms of the extension, Zenosense has the optional
right to fund the development of prospective cancer sensory devices
that may be based on the Sgenia technology. Subject to providing
funding, the Company will have the right to manufacture, market and
sell the resulting devices(s), if developed.
The Company believes the sensory technology and algorithmic
processing in development for MRSA detection could, if successful,
be applied to certain cancer sensory devices. Some cancers, such as
lung and colon, produce volatile organic compounds ("VOCs") in an
individual's breath in a similar way to patients infected with
MRSA. Should the cancer specific pattern of VOCs be identified, the
Company believes that a relatively straightforward modification of
a successful MRSA detection technology may enable it to produce a
similar device for the detection of certain cancers.
Zenosense believes there could be substantial demand for a
relatively low cost, rapid detection device for these types of
cancer. Such a device could allow for much wider screening and the
ability to detect, for example, lung cancer at a much earlier stage
and on a mass scale. Currently lung cancer is typically caught at a
late stage when fewer than 25% of cases can be cured; however, in
Stage I there is a 70% cure rate.
About Zenosense, Inc.
Zenosense, Inc. is a detection device development company based
in Valencia, Spain. Its mission is develop, market and sell an
effective MRSA detector, by way of licensed-in technology, for sale
to healthcare providers for use in clinical settings. The Company
believes there is enormous latent demand for a cost-effective MRSA
detector, driven by the costs associated with the late detection of
MRSA, and that it has identified a valuable new market segment for
a wearable detection device. The development and exclusive license
agreement also includes cancer sensory devices. Find out more at
www.zenosense.net.
Forward-Looking Statements
Statements in this news release that are not statements of
historical fact are forward-looking statements, which are subject
to certain risks and uncertainties. Forward-looking statements can
often be identified by words such as "expects," "intends," "plans,"
"may," "could," "should," "anticipates," "likely," "believes" and
words of similar import. Forward-looking statements are based on
current facts and analyses and other information that are based on
forecasts of future results, estimates of amounts not yet
determined and assumptions of management. Actual results may differ
materially from those expressed or implied by forward-looking
statements due to a variety of factors that may or may not be
foreseeable or within the reasonable control of the Company.
Readers are cautioned not to place undue reliance on such
forward-looking statements. Additional information on risks and
other factors that may affect the business and financial results of
the Company can be found in filings of the Company with the U.S.
Securities and Exchange Commission, including without limitation
the section entitled "Risk Factors" in the Company's Annual Report
on Form 10-K for the year ended December 31, 2013 filed on filed on
March 26, 2014, and in Company reports filed subsequently thereto.
Except as otherwise required by law, the Company disclaims any
obligations or undertaking to publicly release any updates or
revisions to any forward-looking statement contained in this news
release to reflect any change in the Company's expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statement is based.
Contact: Zenosense, Inc. Email: ir@zenosense.net Tel: +34 960
454 202 Web: www.zenosense.net
Zenosense Inc NV (CE) (USOTC:ZENO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Zenosense Inc NV (CE) (USOTC:ZENO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024